Pharmaceutical Applications
|
|
- Charles Williamson
- 6 years ago
- Views:
Transcription
1 Creating an Input Dataset to Produce Incidence and Exposure Adjusted Special Interest AE's Pushpa Saranadasa, Merck & Co., Inc. Abstract Most adverse event (AE) summary tables display the number of patients experiencing an AE in each treatment group and include a standard percentage calculation. This standard way of calculating percentage is the number of patients experiencing an AE divided by the number of patients who were randomized to a particular treatment. But in studies with long-term follow-up, this percentage calculation may not be appropriate because there is a potential for differences in the follow-up duration between treatment groups. A more appropriate measure under this scenario is the exposure-adjusted incidence rate. The exposure-adjusted incidence rate is defined as the number of patients with a particular AE divided by the total exposure-time among patients in the respective treatment group at risk of an initial occurrence of the event. This paper will explain how to create an "input dataset" that can be used to obtain the standard percentage and exposure adjusted incidence rates with a "one proc away" approach. Introduction Safety is a major indicator for drug approval. When a Clinical Study Report (CSR) is submitted there are a number of tables with AE counts and inferential statistics. The duration of a clinical study can range from a few hours to many years. In studies with long-term follow-up, the standard percentage may not be appropriate because there is a potential for differences in the follow-up duration between treatment groups. Additionally, due to the chemical component of a drug given to the study patients, the clinician may desire to identify other defined AE events known as special interest AEs; i.e., those adverse events which are not usually a part of the standard AE dataset. For example, a special interest AE table may require information from domains not of direct concern to the study. These special interest AE events also can be categorized as Tier 1 AE's; some of these AE's are comprised of one or more associated incidents defined in the protocol. This paper focuses on the concept of creating an analysis ready dataset for both standard percentage and exposure adjusted special interest AEs. This is especially important when the information for the special interest events dataset comes from different domains. Objective The objective of this paper is to show how easy it is to create a dataset that can be used to output desired study results such as frequencies, proportions, AE rates and p-values using a one proc away method. 1
2 Procedure with an Example Throughout the paper special interest AEs are referred to as EVENTS and the AE incidences associated with those EVENTS are referred to as EVNTTERM. Figure 1 is the mock-up that illustrates the outcome of producing the dataset being discussed here. You can see how events and evntterms and the corresponding statistics are displayed. Figure 1 Number (%) of Patients with Special Interest AE 's by Treatment Group All Treated Patients Number (%) of AE Difference in Proportion of AE AE Rates Per Patient-years of Exposure TRT1 TRT2 TRT1 minus TRT2 TRT1 TRT2 XXX XXX Diff. (95% CI ) p-value With Diabetes xx(x.x) xx(x.x) x.x(x.x,x.x).xxx.xxx.xxx Anti-diabetic medications xx(x.x) xx(x.x) x.x(x.x,x.x) Elevations of Fasting xx(x.x) xx(x.x) x.x(x.x,x.x) Diabetes mellitus xx(x.x) xx(x.x) x.x(x.x,x.x) type 2 mellitus xx(x.x) xx(x.x) x.x(x.x,x.x) With worsening xx(x.x) xx(x.x) x.x(x.x,x.x).xxx.xxx.xxx Tolerances Fasting >100 xx(x.x) xx(x.x) x.x(x.x,x.x) Consecutive Elevations of xx(x.x) xx(x.x) x.x(x.x,x.x) Fasting Hyperglycemia xx(x.x) xx(x.x) x.x(x.x,x.x) Blood increased xx(x.x) xx(x.x) x.x(x.x,x.x) CI = Confidence intervals. Calculated using a method based on Wilson's score method. p-values are from Fisher's Exact test. AE rates per patient-years of exposure = (number of patients with AE/sum of days at risk for AE) x days/year. The following section explains how to create a dataset in such a way as to get all the information needed for reporting the desired statistics. 2
3 STEP 1 Identifying EVENTS: How many events are specified in the protocol? What event terms are associated with an event? The answers to these questions are determined by clinicians and are included in the study protocol. If there are 10 events to be included in the desired table then it is necessary to precisely understand what they are and how they are defined. For easy programming assign a numeric code to each event. For example, when there are only three events the numeric code would be 1= ' Diabetes' 2 = 'Worsening Tolerances' 3= 'ALT/AST elevations with muscle symptoms' Look at the hypothetical example in Figure 1 above, "Diabetes" is an event of interest and event terms are then listed as associated event terms for the main event. In this figure the event terms are "anti medication" taken from the CM (Concomitant Medications) domain, OR "elevations of fasting glucose" taken from the LB (Lab) domain OR "any AE s related to " (terms should be defined) taken from the AE domain. At this stage it is important to understand how the conditions of associated event terms are combined. The combinations could be either "OR", "AND", or both. Depending on the conditions for event terms the set or merge statements should be applied in order to reflect the conditions. Another hypothetical example: "Worsening of Tolerance" can be another event of interest. It can be defined as "not on anti-diabetic medications during pre treatment period" from CM domain AND "no medical history of " from MH (Medical History) domain AND "baseline Fasting glucose < 100" from LB domain AND "no onset terms" defined from AE domain AND "on treatment fasting >100" OR "two consecutive fasting glucose elevations" from LB domain OR "any terms related to indicate glucose tolerances" from AE domain. STEP 2 The next step is to capture the necessary information from each domain related to the incidents of interest. Make sure all the event dates are within the range defined in the protocol. The data should appear as in Figure 2 after assembling the data from each domain. 3
4 STEP 3 The following code captures the first incidence of each unique event term. Proc sort data=event; by subjid evntterm evntdt; - data event1; set event; by subjid evntterm evntdt; If first.evntterm; termfl =1; flag the unique associated event term per patient. Figure 2 EVENT dataset SUBJECT EVENT EVNTDT EVNTTERM EVNTCODE EVNTVALU 101 Diabetes 02/05/10 anti diabetic 1 1 medication 101 Diabetes 02/07/10 anti diabetic 1 1 medication 101 Diabetes 01/12/10 anti diabetic 1 1 medication 101 Diabetes 01/12/10 Increasing Diabetes 01/10/10 Increasing Diabetes 01/29/10 mellitus Diabetes 01/05/10 mellitus Diabetes 02/12/10 insulin resistant Diabetes 02/15/10 type mellitus 101 Diabetes 01/04/10 type mellitus 104 Diabetes 05/09/10 Increasing Diabetes 06/03/10 insulin resistant Diabetes 06/10/10 latent 1 1 autoimmune 104 Diabetes 07/02/10 latent autoimmune 1 1 4
5 The above sorting criteria should be applied for each event with associated event terms. Once we append all events you will have a dataset with all events and their associated event terms. The question then arises as to how we can get AE rates for each of the events? AE rates are calculated by summing all events (Yes, No) and dividing by sum of the times to the first event in the case of those subjects with an AE plus the total exposure of those reporting no event. It becomes evident that in order to do the AE rate calculations we need to find the patients who are included in the denominator but did not have any events. Briefly on needs to get the unique patients that will be in the denominator and create EVENTS dummies for them. If there are 10 EVENTS for each patient then the code that creates the set of dummies is: STEP 4 proc sort data=derived.adsl out=adme; by subjid; data dummy; set adme; by subjid; do evntcode = 1 to 10; output; end; Merge data set that was created for the event terms and merge with the just created dummy dataset by subjid and evntcode in order to assign event for each patient. STEP 5 data allevent; merge event(in=b)dummy(in=a) ; by subjid evntcode; if a and not b then evntvalu=0; <- assigning 0 when there are no any events. Apply this condition to capture the duration of the staying on the study for patients if evntvalu = 1 then toevent = (evntdt -stsdt)/365.25; if evntvalu= 0 then toevent = (stedt - stsdt)/365.25;. 5
6 STEP 6 Data tmevnt; set allevent; by an evntcode evntdt; if first.evntcode then evntfl = 1; <- this captures the first date of the event for each patient The final dataset with selected variables should appear as shown in Figure 3 Figure 3 SUBJID EVENT EVNTDT EVNTTERM EVNTCODE EVNTVALU EVNTFL TERMFL 101 Diabetes 01/04/10 Type Diabetes mellitus 101 Diabetes 01/05/10 Diabetes mellitus 101 Diabetes 01/10/10 Increasing Diabetes 01/12/10 Anti medication 101 Diabetes 02/12/10 Insulin resistant Diabetes Diabetes Diabetes 05/09/10 Increasing Diabetes 06/03/10 Insulin resistant Diabetes 06/10/10 Latent autoimmune 101 FG Tolerances 03/08/2010 FG > FG Tolerances 04/11/ Hyperglycemia 102 FG Tolerances 06/20/2010 Blood Increase 102 FG Tolerances 06/27/2010 Hyperglycemia FG Tolerances 01/22/2010 Consecutive elevation of FG 103 FG Tolerances 02/02/2010 Blood Increase 103 FG Tolerances 03/12/2010 Hyperglycemia FG Tolerances
7 Why is this process one proc away? With this simple code AE counts and rates for each EVENTS can be produced. proc sql; create table ae2 as select distinct evntcode, trtmnt, sum(evntvalu) as COUNTS counts for each event,put (round(sum(evntvalu)/sum(toevent),.001), 5.3) as AERATES from tmevnt where evntfl=1 group by trtmnt, evntcode order by evntcode; quit; After running the code you will have an output dataset as shown in Figure 4 Figure 4 TRTMNT EVNTCODE COUNTS AERATES TRT TRT TRT TRT TRT TRT TRT TRT TRT TRT Getting counts for each of the associated terms under each of the events is simple: proc freq data=tmevnt ; where evntterm ne ' ' and termfl=1; /*counts for each evntterm by evntcode and trtmnt*/ tables evntcode*evntterm*trtmnt/out=fterms; Make sure all the patients in the denominator are in the main dataset Finally, after making sure of the proper subsetting, the p-values for each event are computed as: proc freq data=tmevnt; where evntfl=1; tables evntcode*trtmnt*evntvalu/ exact fisher ; ods output FishersExact=fishall(where=(NAME1='XP2_FISH')); 7
8 Conclusion In this paper we considered the specific example of creating a one proc away dataset for the presentation of specific interest AE tables. There are certain ways in which a programmer can create datasets to produce desired results. The most important thing to understand is the specific result that we need to produce and how can it be done efficiently without any manipulations in the tables program. Two essential features are common to all one proc away datasets. First, there must be clear dataset specifications. Second, there must be clear mock-ups for the tables. If the one proc away datasets are analysis ready then the whole analytical process is efficient and can save a lot of time. References SAS Institute Inc. 2004, SQL Processing with SAS Course Notes Acknowledgments Thank you to Ram Radhakrishnan for reviewing this work and providing constructive feedback. AUTHOR CONTACT Your comments and questions are valued and welcome. Contact the author at: Pushpa Saranadasa Phone: (267) Pushpa_saranadasa@merck.com SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc. in the USA and other countries. indicates USA registration. 8
PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables
PharmaSUG 2012 - Paper IB09 PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables Sneha Sarmukadam, Statistical Programmer, PharmaNet/i3, Pune, India Sandeep
More informationA SAS sy Study of ediary Data
A SAS sy Study of ediary Data ABSTRACT PharmaSUG 2017 - Paper BB14 A SAS sy Study of ediary Data Amie Bissonett, inventiv Health Clinical, Minneapolis, MN Many sponsors are using electronic diaries (ediaries)
More informationProgrammatic Challenges of Dose Tapering Using SAS
ABSTRACT: Paper 2036-2014 Programmatic Challenges of Dose Tapering Using SAS Iuliana Barbalau, Santen Inc., Emeryville, CA Chen Shi, Santen Inc., Emeryville, CA Yang Yang, Santen Inc., Emeryville, CA In
More informationAE: An Essential Part of Safety Summary Table Creation. Rucha Landge, Inventiv International Pharma Services Pvt. Ltd.
PharmaSUG 2016 - Paper IB11 AE: An Essential Part of Safety Summary Table Creation. Rucha Landge, Inventiv International Pharma Services Pvt. Ltd., Pune, India ABSTRACT Adverse event (AE) summary tables
More informationPharmaSUG Paper QT38
PharmaSUG 2015 - Paper QT38 Statistical Review and Validation of Patient Narratives Indrani Sarkar, inventiv Health Clinical, Indiana, USA Bradford J. Danner, Sarah Cannon Research Institute, Tennessee,
More informationStatistical Analysis Plan RH01649 Version Document Identifier Effective Date eldo_clinical_doc Reason For Issue
STATISTICAL ANALYSIS PLAN FOR PROTOCOL RH01649 A Study to Assess Efficacy over Placebo and Speed of Onset of Pain Relief of New Panadol Extra as Compared to Ibuprofen in Episodic Tension Headache BIOSTATISTICS
More informationImputing Dose Levels for Adverse Events
Paper HO03 Imputing Dose Levels for Adverse Events John R Gerlach & Igor Kolodezh CSG Inc., Raleigh, NC USA ABSTRACT Besides the standard reporting of adverse events in clinical trials, there is a growing
More informationExtract Information from Large Database Using SAS Array, PROC FREQ, and SAS Macro
SESUG 2016 Paper CC-160 Extract Information from Large Database Using SAS Array, PROC FREQ, and SAS Macro Lifang Zhang, Department of Biostatistics and Epidemiology, Augusta University ABSTRACT SAS software
More informationCollapsing Longitudinal Data Across Related Events and Imputing Endpoints
Collapsing Longitudinal Data Across Related Events and Imputing Endpoints James Joseph, INC Research, King of Prussia, PA INTRODUCTION When attempting to answer a research question, the best study design
More informationABSTRACT INTRODUCTION
Adaptive Randomization: Institutional Balancing Using SAS Macro Rita Tsang, Aptiv Solutions, Southborough, Massachusetts Katherine Kacena, Aptiv Solutions, Southborough, Massachusetts ABSTRACT Adaptive
More informationUsing Direct Standardization SAS Macro for a Valid Comparison in Observational Studies
T07-2008 Using Direct Standardization SAS Macro for a Valid Comparison in Observational Studies Daojun Mo 1, Xia Li 2 and Alan Zimmermann 1 1 Eli Lilly and Company, Indianapolis, IN 2 inventiv Clinical
More informationOCCDS Creating flags or records. Rob Wartenhorst PhUSE Barcelona 2016
OCCDS Creating flags or records Rob Wartenhorst PhUSE Barcelona 2016 Introduction ADAE, ADCM and ADMH originally set up using ADAE structure. After release of OCCDS guide attempted to implement the occurrence
More informationImplementing Worst Rank Imputation Using SAS
Paper SP12 Implementing Worst Rank Imputation Using SAS Qian Wang, Merck Sharp & Dohme (Europe), Inc., Brussels, Belgium Eric Qi, Merck & Company, Inc., Upper Gwynedd, PA ABSTRACT Classic designs of randomized
More informationInverse Probability of Censoring Weighting for Selective Crossover in Oncology Clinical Trials.
Paper SP02 Inverse Probability of Censoring Weighting for Selective Crossover in Oncology Clinical Trials. José Luis Jiménez-Moro (PharmaMar, Madrid, Spain) Javier Gómez (PharmaMar, Madrid, Spain) ABSTRACT
More informationGraph Display of Patient Profile Using SAS
PharmaSUG 2018 - Paper DV-17 Graph Display of Patient Profile Using SAS Yanwei Han, Seqirus USA Inc., Cambridge, MA Hongyu Liu, Seqirus USA Inc., Cambridge, MA ABSTRACT We usually create patient profile
More informationCreating Multiple Cohorts Using the SAS DATA Step Jonathan Steinberg, Educational Testing Service, Princeton, NJ
Creating Multiple Cohorts Using the SAS DATA Step Jonathan Steinberg, Educational Testing Service, Princeton, NJ ABSTRACT The challenge of creating multiple cohorts of people within a data set, based on
More informationGuidelines for HCHS/SOL Manuscript Verification Version 1.0 (August 14, 2012)
Guidelines for HCHS/SOL Manuscript Verification Version 1.0 (August 14, 2012) Introduction Commonly accepted best practices in the biostatistics field include the independent verification of the data management
More informationSystematic Inductive Method for Imputing Partial Missing Dates in Clinical Trials
Paper PO05 Systematic Inductive Method for Imputing Partial Missing Dates in Clinical Trials Ping Liu ABSTRACT In any phase of clinical trials, dates are very critical throughout the entire trial. However,
More informationStata: Merge and append Topics: Merging datasets, appending datasets - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1. Terms There are several situations when working with
More informationPharmaSUG China 2018 Paper SP-28
PharmaSUG China 2018 Paper SP-28 SAS Macros for the Area Under the Curve (AUC) Calculation of Continuous Glucose Monitoring (CGM) Data Xiao Ran Han, The Chinese University of Hong Kong, China Ka Chun Chong,
More informationWhat Are Your Odds? : An Interactive Web Application to Visualize Health Outcomes
What Are Your Odds? : An Interactive Web Application to Visualize Health Outcomes Abstract Spreading health knowledge and promoting healthy behavior can impact the lives of many people. Our project aims
More informationStandards for Analyzable Submission Datasets for Directed Safety Analyses
Standards for Analyzable Submission Datasets for Directed Safety Analyses Michael Nessly Director, Clinical Biostatistics Merck Research Labs CDISC Analysis Dataset Models Team (ADaM) nesslym@merck.com
More informationHUNGER-RELIEF ORGANIZATION TOOLKIT
HUNGER-RELIEF ORGANIZATION TOOLKIT Contents Welcome to the #GiveHealthy Movement! 2 What s your role as a #GiveHealthy organization? 2 Why should your organization join the #GiveHealthy Movement? 2 How
More informationDoes factor indeterminacy matter in multi-dimensional item response theory?
ABSTRACT Paper 957-2017 Does factor indeterminacy matter in multi-dimensional item response theory? Chong Ho Yu, Ph.D., Azusa Pacific University This paper aims to illustrate proper applications of multi-dimensional
More informationImproved Transparency in Key Operational Decisions in Real World Evidence
PharmaSUG 2018 - Paper RW-06 Improved Transparency in Key Operational Decisions in Real World Evidence Rebecca Levin, Irene Cosmatos, Jamie Reifsnyder United BioSource Corp. ABSTRACT The joint International
More informationADaM Tips for Exposure Summary
ABSTRACT PharmaSUG China 2016 Paper 84 ADaM Tips for Exposure Summary Kriss Harris, SAS Specialists Limited, Hertfordshire, United Kingdom Have you ever created the Analysis Dataset for the Exposure Summary
More informationA SAS Macro to Present a Summary Table of the Number of Patients Having Experienced Adverse Events in a Clinical Trial
A SAS Macro to Present a Summary Table of the Number of Patients Having Experienced Adverse Events in a Clinical Trial Christoph Gerlinger * and Ursula Franke ** * Laboratoires Fournier S.C.A. and ** biodat
More informationPaper number: CC02 MACRO %NEWFLOW JIAN HUA (DANIEL) HUANG, FOREST LABORATORIES INC, NJ
Paper number: CC02 MACRO %NEWFLOW JIAN HUA (DANIEL) HUANG, FOREST LABORATORIES INC, NJ ABSTRACT: If you use SAS Proc Report frequently, you will be familiar with the flow option. The flow option wraps
More informationBOOKLET ONE. Introduction to Behavioural Activation for Depression
BEHAVIOURAL ACTIVATION FOR DEPRESSION BOOKLET ONE Introduction to Behavioural Activation for Depression Contents Missing sources of wellbeing 2-3 Sources of misery 4-5 What we do when we feel down 6-7
More informationBlueBayCT - Warfarin User Guide
BlueBayCT - Warfarin User Guide December 2012 Help Desk 0845 5211241 Contents Getting Started... 1 Before you start... 1 About this guide... 1 Conventions... 1 Notes... 1 Warfarin Management... 2 New INR/Warfarin
More informationKick It Old School - Creating Reports with the DATA _NULL_ Step
Kick It Old School - Creating Reports with the DATA _NULL_ Step Sai Ma, PharmaNet/i3, Toronto, Ontario Canada Suwen Li, Everest Clinical Research Services Inc., Markham, Ontario Canada Minlan Li, Everest
More informationGenerate Informative Clinical Laboratory Results Listing
PharmaSUG2011 - Paper PO02 Generate Informative Clinical Laboratory Results Listing Sai Ma, Everest Clinical Research Services Inc., Markham, Ontario Canada ABSTRACT Clinical laboratory results review
More informationIntroduction to SPSS S0
Basic medical statistics for clinical and experimental research Introduction to SPSS S0 Katarzyna Jóźwiak k.jozwiak@nki.nl November 10, 2017 1/55 Introduction SPSS = Statistical Package for the Social
More informationA SAS Macro to Investigate Statistical Power in Meta-analysis Jin Liu, Fan Pan University of South Carolina Columbia
Paper 109 A SAS Macro to Investigate Statistical Power in Meta-analysis Jin Liu, Fan Pan University of South Carolina Columbia ABSTRACT Meta-analysis is a quantitative review method, which synthesizes
More informationFrequency Tables Aspects to Consider / PhUSE - Industry Starters / Katja Glaß
Frequency Tables Aspects to Consider 15.10.2014 / PhUSE - Industry Starters / Katja Glaß Agenda Introduction Do the double programming Demography Adverse Events Laboratory Summary and further aspects Page
More informationUsing CDISC Models for the Analysis of Safety Data
Paper RA02 Using CDISC Models for the Analysis of Safety Data Susan J. Kenny, Inspire Pharmaceuticals Inc. Research Triangle Park, NC, USA Edward D. Helton, SAS Institute, Cary, NC, USA ABSTRACT The collection
More informationLet s get started with the OneTouch Reveal web app
Let s get started with the Step-by-Step Guide Your step-by-step guide to setting up and using the with the OneTouch Reveal mobile app The supporting you and your patients throughout their journey Designed
More informationInpatient Insulin: A Team Approach
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/inpatient-insulin-a-team-approach/3763/
More informationThis report summarizes the stakeholder feedback that was received through the online survey.
vember 15, 2016 Test Result Management Preliminary Consultation Online Survey Report and Analysis Introduction: The College s current Test Results Management policy is under review. This review is being
More informationmehealth for ADHD Parent Manual
mehealth for ADHD adhd.mehealthom.com mehealth for ADHD Parent Manual al Version 1.0 Revised 11/05/2008 mehealth for ADHD is a team-oriented approach where parents and teachers assist healthcare providers
More informationLab 8: Multiple Linear Regression
Lab 8: Multiple Linear Regression 1 Grading the Professor Many college courses conclude by giving students the opportunity to evaluate the course and the instructor anonymously. However, the use of these
More informationUsing the NWD Integrative Screener as a Data Collection Tool Agency-Level Aggregate Workbook
Using the NWD Integrative Screener as a Data Collection Tool Agency-Level Aggregate Workbook The NWD Integrative Screener was designed to be user friendly for providers and agencies. Many items and health
More informationAnalysis of Environmental Data Conceptual Foundations: En viro n m e n tal Data
Analysis of Environmental Data Conceptual Foundations: En viro n m e n tal Data 1. Purpose of data collection...................................................... 2 2. Samples and populations.......................................................
More informationBaseline Mean Centering for Analysis of Covariance (ANCOVA) Method of Randomized Controlled Trial Data Analysis
MWSUG 2018 - Paper HS-088 Baseline Mean Centering for Analysis of Covariance (ANCOVA) Method of Randomized Controlled Trial Data Analysis Jennifer Scodes, New York State Psychiatric Institute, New York,
More information2017 Medicare CAHPS At-A-Glance Report
2017 Medicare CAHPS At-A-Glance Report CMS MA PD Contract: H9207 Project Number(s): 30120117 and 10123759 Current data as of: 07/10/2017 1965 Evergreen Boulevard Suite 100, Duluth, Georgia 30096 2017 At-A-Glance
More informationGLUTEN-FREE FOOD SCHEME. Information Pack
GLUTEN-FREE FOOD SCHEME Information Pack The Tayside Gluten-Free Food Scheme is part of the Scottish Gluten-Free Food Service. There are variations from the Scottish Service and more information can be
More informationDo the sample size assumptions for a trial. addressing the following question: Among couples with unexplained infertility does
Exercise 4 Do the sample size assumptions for a trial addressing the following question: Among couples with unexplained infertility does a program of up to three IVF cycles compared with up to three FSH
More informationDesign and Construct Efficacy Analysis Datasets in Late Phase Oncology Studies
PharmaSUG China Design and Construct Efficacy Analysis s in Late Phase Oncology Studies Huadan Li, MSD R&D (China) Co., Ltd., Beijing, China Changhong Shi, MSD R&D (China) Co., Ltd., Beijing, China ABSTRACT
More informationSHARED DECISION MAKING WORKSHOP SMALL GROUP ACTIVITY LUNG CANCER SCREENING ROLE PLAY
SHARED DECISION MAKING WORKSHOP LUNG CANCER SCREENING ROLE PLAY Instructions Your group will role play a Shared Decision Making (SDM) conversation around lung cancer screening using the provided scenario.
More informationEvaluation: Controlled Experiments. Title Text
Evaluation: Controlled Experiments Title Text 1 Outline Evaluation beyond usability tests Controlled Experiments Other Evaluation Methods 2 Evaluation Beyond Usability Tests 3 Usability Evaluation (last
More informationRegistered Radiologist Assistant (R.R.A. ) 2016 Examination Statistics
Registered Radiologist Assistant (R.R.A. ) Examination Statistics INTRODUCTION This report summarizes the results of the Registered Radiologist Assistant (R.R.A. ) examinations developed and administered
More informationMaking comparisons. Previous sessions looked at how to describe a single group of subjects However, we are often interested in comparing two groups
Making comparisons Previous sessions looked at how to describe a single group of subjects However, we are often interested in comparing two groups Data can be interpreted using the following fundamental
More informationMethodology for Non-Randomized Clinical Trials: Propensity Score Analysis Dan Conroy, Ph.D., inventiv Health, Burlington, MA
PharmaSUG 2014 - Paper SP08 Methodology for Non-Randomized Clinical Trials: Propensity Score Analysis Dan Conroy, Ph.D., inventiv Health, Burlington, MA ABSTRACT Randomized clinical trials serve as the
More information2016 Children and young people s inpatient and day case survey
NHS Patient Survey Programme 2016 Children and young people s inpatient and day case survey Technical details for analysing trust-level results Published November 2017 CQC publication Contents 1. Introduction...
More informationWHY NEW MEMBERSHIP OFFERINGS AND WHO DECIDED ON THE CHANGE
WHY NEW MEMBERSHIP OFFERINGS AND WHO DECIDED ON THE CHANGE Why are these changes being made? As the landscape of member organizations continues to change, to remain relevant to shifts in our profession,
More informationADDRESSING CHRONIC DISEASES
ADDRESSING CHRONIC DISEASES Health-Management Strategies for Use with Behavioral Health Clients Mary Brunette, MD Delia Cimpean Hendrick, MD SCOPE AND SEQUENCE For more information about this program,
More informationIntroducing DIA-TEC CLOUDTM. Technology. Education. Community. Your NEW Strategy for Diabetes Cost Management from the Experts at DECM
Introducing DIA-TEC CLOUDTM Technology. Education. Community. Your NEW Strategy for Diabetes Cost Management from the Experts at DECM Technology. Education. Community. Diabetes happens in real time. Now,
More informationIt s time to TALK Targets A guide on using TALK Targets with your patients
It s time to TALK Targets A guide on using TALK Targets with your patients The TALK Targets campaign was initiated and fully funded by Novo Nordisk. 2 TALK Targets is a patient support campaign for people
More informationV-Go : Simple to start, easy to use
V-Go : Simple to start, easy to use Patient Start Guide Make multiple daily insulin shots a thing of the past. Take control with V-Go. V-Go Customer Care personalized 1-on-1 support for you Call 1-866-881-1209
More informationThe Epidemic Model 1. Problem 1a: The Basic Model
The Epidemic Model 1 A set of lessons called "Plagues and People," designed by John Heinbokel, scientist, and Jeff Potash, historian, both at The Center for System Dynamics at the Vermont Commons School,
More informationLev Sverdlov, Ph.D.; John F. Noble, Ph.D.; Gabriela Nicolau, Ph.D. Innapharma, Inc., Upper Saddle River, NJ
THE RESULTS OF CLUSTER ANALYSIS OF CLINICAL DATA USING THE FASTCLUS PROCEDURE Lev Sverdlov, Ph.D.; John F. Noble, Ph.D.; Gabriela Nicolau, Ph.D. Innapharma, Inc., Upper Saddle River, NJ ABSTRACT The objective
More informationReview of compliance. Mercia Care Homes Limited Sefton Park. South West. Region: Sefton Park 10 Royal Crescent Weston-super-Mare Somerset BS23 2AX
Review of compliance Mercia Care Homes Limited Sefton Park Region: Location address: Type of service: South West Sefton Park 10 Royal Crescent Weston-super-Mare Somerset BS23 2AX Residential substance
More informationExamples: Tables. Descriptive stats with ANOVA, ANCOVA, and t test p values Frequency and percent Correlation coefficients
Examples: Tables Descriptive stats with ANOVA, ANCOVA, and t test p values Frequency and percent Correlation coefficients Descriptive Statistics Table 1. Body Mass Index using Last Observation Carried
More informationThank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationTreatment Adaptive Biased Coin Randomization: Generating Randomization Sequences in SAS
Adaptive Biased Coin Randomization: OBJECTIVES use SAS code to generate randomization s based on the adaptive biased coin design (ABCD) must have approximate balance in treatment groups can be used to
More informationStepwise method Modern Model Selection Methods Quantile-Quantile plot and tests for normality
Week 9 Hour 3 Stepwise method Modern Model Selection Methods Quantile-Quantile plot and tests for normality Stat 302 Notes. Week 9, Hour 3, Page 1 / 39 Stepwise Now that we've introduced interactions,
More informationApplication Highlights. Sample Reports.
Application Highlights -- Dashboard -- Activity Summary -- Therapy Timeline -- Blood Glucose Trends -- Pump Settings -- Save and Share Sample Reports www.tandemdiabetes.com/tconnect Dashboard Helps you
More informationEvaluation: Scientific Studies. Title Text
Evaluation: Scientific Studies Title Text 1 Evaluation Beyond Usability Tests 2 Usability Evaluation (last week) Expert tests / walkthroughs Usability Tests with users Main goal: formative identify usability
More informationMeasure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care
Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION: All patients
More informationCARE Cross-project Collectives Analysis: Technical Appendix
CARE Cross-project Collectives Analysis: Technical Appendix The CARE approach to development support and women s economic empowerment is often based on the building blocks of collectives. Some of these
More informationA SAS Application for Analyzing Quality of Life data: NCIC-CTG Standard Method
Paper SP01 A SAS Application for Analyzing Quality of Life data: NCIC-CTG Standard Method Don (Dongguang) Li, NCIC-CTG, Queen s University, Kingston, ON, Canada ABSTRACT The Health-Related Quality of Life
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationThe Spine Institute for Quality Conservative Care QCDR, Powered by Premier, Inc.
The Spine Institute for Quality Conservative Care QCDR, Powered by Premier, Inc. 2018 non-mips Measure Specifications Last updated March 7, 2018 SPINEIQ5: Change in Functional Outcomes- National Quality
More informationOutcome Measure Considerations for Clinical Trials Reporting on ClinicalTrials.gov
Outcome Measure Considerations for Clinical Trials Reporting on ClinicalTrials.gov What is an Outcome Measure? An outcome measure is the result of a treatment or intervention that is used to objectively
More informationADaM Grouping: Groups, Categories, and Criteria. Which Way Should I Go?
ABSTRACT PharmaSUG 2017 - Paper DS17 ADaM Grouping: Groups, Categories, and Criteria. Which Way Should I Go? Jack Shostak, Duke Clinical Research Institute ADaM has variables that allow you to cluster,
More informationChapter 13 Estimating the Modified Odds Ratio
Chapter 13 Estimating the Modified Odds Ratio Modified odds ratio vis-à-vis modified mean difference To a large extent, this chapter replicates the content of Chapter 10 (Estimating the modified mean difference),
More informationConsultation on renaming the Local anaesthetics and Prescription only medicines annotations for chiropodists / podiatrists
Consultation on renaming the Local anaesthetics and Prescription only medicines annotations for chiropodists / podiatrists 1. Introduction 1.1 We are the Health and Care Professions Council (HCPC). This
More informationCQC s plans for the questions it asks NHS patients
CQC s plans for the questions it asks NHS patients Easy read (May 2016) This is an easy read version of the document Consultation: CQC s NHS Patient Survey Programme (May 2016). It asks you questions about
More informationSimple Linear Regression One Categorical Independent Variable with Several Categories
Simple Linear Regression One Categorical Independent Variable with Several Categories Does ethnicity influence total GCSE score? We ve learned that variables with just two categories are called binary
More informationWellness Recovery Action Planning (WRAP) WRAP is designed and managed by you and is designed to
Wellness Recovery Action Planning (WRAP) WRAP is designed and managed by you and is designed to Decrease and prevent intrusive or troubling feelings and behaviours Increase personal empowerment Improve
More informationGetting Started. Learning Guide. with Insulin Pump Therapy. PUMP Foundations. for the MiniMed 530G with Enlite
Getting Started with Insulin Pump Therapy for the MiniMed 530G with Enlite Learning Guide PUMP Foundations MiniMed 530G Insulin Pump Settings Form: We recommend that you record all settings on this form
More informationAutomated Immunization Evaluation Process
University of Medicine and Dentistry of New Jersey - University of Pennsylvania New Jersey Comprehensive Immunization Program (NJ-CIP) Automated Immunization Evaluation Process Working Paper rev. May 11,
More information@ Lipitor And Type 2 Diabetes?? Diabetes Symptoms Skin treatment options we have to control diabetes to Meal Plan; Type 1 Diabetes Diet Menu;
Living With Diabetes Type1 Or Type 2: The Symptoms, Diagnosis & Treatment Of Diabetes: ( Diabetes Meal Planning, Type 2 Diabetes, Diabetes For Dummies, Diabetes Control, Diabetes Diet, Treatment) By Michael
More information4/14/2016. Take ownership of the care - This is my patient!
Guidelines and Training in how to be a Emergency Health Professional NAVIGATOR 2016 Paul Stiegler MD FACEP Medical Director EMD Dane County PSCC Onstar LLC Take ownership of the care - This is my patient!
More informationReimbursement Guide. Hospital Outpatient. Please see Important Safety Information on page 2 and click here for full Prescribing Information.
Reimbursement Guide Hospital Outpatient Information provided in this resource is for informational purposes only and does not guarantee that codes will be appropriate or that coverage and reimbursement
More informationStudy Participants HbA1c (%, mean and SD) Duration of diabetes (years, mean and SD) Age (years, mean and SD) Type 1 diabetes
Supplementary Table 1. Baseline characteristics of the included studies and participants Name (year) Type 1 diabetes Length (mths) (2013) 14 6 I:63 C:64 (2010) 15 6 I:67 C:63 Charpentier et al. (2013)
More informationFor patients uncontrolled on multiple daily injections of insulin. A quick-start guide for your practice ALL-DAY CONTROL WITH
For patients uncontrolled on multiple daily injections of insulin A quick-start guide for your practice Dosing guidance 1,* V-Go: 3 options 1 For initiating V-Go in patients switching from MDI The majority
More informationNumerical Integration of Bivariate Gaussian Distribution
Numerical Integration of Bivariate Gaussian Distribution S. H. Derakhshan and C. V. Deutsch The bivariate normal distribution arises in many geostatistical applications as most geostatistical techniques
More informationBiostatistics and Design of Experiments Prof. Mukesh Doble Department of Biotechnology Indian Institute of Technology, Madras
Biostatistics and Design of Experiments Prof Mukesh Doble Department of Biotechnology Indian Institute of Technology, Madras Lecture 02 Experimental Design Strategy Welcome back to the course on Biostatistics
More informationThe FASTCLUS Procedure as an Effective Way to Analyze Clinical Data
The FASTCLUS Procedure as an Effective Way to Analyze Clinical Data Lev Sverdlov, Ph.D., Innapharma, Inc., Park Ridge, NJ ABSTRACT This paper presents an example of the fast cluster analysis (SAS/STAT,
More informationMeasure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care
Measure #412: Documentation of Signed Opioid Treatment Agreement National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:
More informationStep 3 Tutorial #3: Obtaining equations for scoring new cases in an advanced example with quadratic term
Step 3 Tutorial #3: Obtaining equations for scoring new cases in an advanced example with quadratic term DemoData = diabetes.lgf, diabetes.dat, data5.dat We begin by opening a saved 3-class latent class
More informationIntegrated ADSL. PhUSE Nate Freimark/Thomas Clinch Theorem Clinical Research
Integrated ADSL PhUSE 2012-10-17 Nate Freimark/Thomas Clinch Theorem Clinical Research ADSL - Not Without Challenges Where to Begin Source Data One ADSL or Two Number of Records per Subject Update or Create
More informationmyphonak app User Guide
myphonak app User Guide Getting started myphonak is an app developed by Sonova, the world leader in hearing solutions based in Zurich, Switzerland. Read the user instructions thoroughly in order to benefit
More informationIn-hospital Intensive Care Unit Mortality Prediction Model
In-hospital Intensive Care Unit Mortality Prediction Model COMPUTING FOR DATA SCIENCES GROUP 6: MANASWI VELIGATLA (24), NEETI POKHARNA (27), ROBIN SINGH (36), SAURABH RAWAL (42) Contents Impact Problem
More informationA Group Representative s Guide to the Virginia Area Assembly
Al-Anon Family Groups, Area 57 A Group Representative s Guide to the Virginia Area Assembly Revised Oct. 8, 2017 Table of Contents Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Assembly Definition Assembly
More informationCombining Electronic Diary Seizure Data with Visit-Based Seizure Data in the MONEAD Study
PharmaSUG 2018 - Paper RW-02 Combining Electronic Diary Seizure Data with Visit-Based Seizure Data in the MONEAD Study Julia Skinner and Ryan May, Emmes Corporation ABSTRACT Electronic diary (ediary) mobile
More informationWelcome back to our program!
Welcome back to our program! 1 As you likely recall, the SBIRT TIPS training program is a federally funded project that aims to both educate practitioner students and impact health systems. 2 Let s start
More informationBest practices for a successful wellness screening program
Health & Wellness Best practices for a successful wellness screening program Identify risk. Increase engagement. Incite change. Identifying health risks in your employee population People at risk for chronic
More informationModernizing the Mitral Valve: Advances in Robotic and Minimally Invasive Cardiac Repair
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/modernizing-mitral-valveadvances-robotic-minimally-invasive-cardiac-repair/7686/
More information